Literature DB >> 7130986

KB cell culture I. Role in discovery of antitumor agents from higher plants.

R E Perdue.   

Abstract

KB (Eagle) cell culture has played a powerful role in discovery of antitumor agents from higher plants. Had KB alone been used as a preliminary screen, with in vivo screening limited to KB-active extracts, fractions, or compounds, KB activity of crude products would have led to discovery of vinblastine, vincristine, podophyllotoxin (from which the semisynthetics VM-26 and VP-16 were derived), and all but one of the antitumor agents now under development toward or in clinical evaluation, including bouvardin, bruceantin, camptothecin, ellipticine, homoharringtonine, maytansine, taxol, thalicarpine, and tripdiolide. Indicine N-oxide is the only important antitumor agent which would have been discovered only by in vivo screening of crude plant products. A substantial number of compounds effective against lymphoid leukemia L1210 and B16 melanoma were isolated from plants, extracts of which were active against KB.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7130986     DOI: 10.1021/np50022a010

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  3 in total

1.  The clinical relevance of cancer cell lines.

Authors:  Jean-Pierre Gillet; Sudhir Varma; Michael M Gottesman
Journal:  J Natl Cancer Inst       Date:  2013-02-21       Impact factor: 13.506

2.  Search for hydrophilic marine fungal metabolites: a rational approach for their production and extraction in a bioactivity screening context.

Authors:  Carine Le Ker; Karina-Ethel Petit; Jean-François Biard; Joël Fleurence
Journal:  Mar Drugs       Date:  2011-01-10       Impact factor: 5.118

Review 3.  Medicinal Plants and Other Living Organisms with Antitumor Potential against Lung Cancer.

Authors:  Luara de Sousa Monteiro; Katherine Xavier Bastos; José Maria Barbosa-Filho; Petrônio Filgueiras de Athayde-Filho; Margareth de Fátima Formiga Melo Diniz; Marianna Vieira Sobral
Journal:  Evid Based Complement Alternat Med       Date:  2014-07-24       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.